Literature DB >> 3800643

Increased susceptibility to infection due to infusion of exogenous chemotaxin.

R W Yurt, G T Shires.   

Abstract

Previous studies indicate that endogenous chemotaxins, such as the chemotactic factor C5a, may modulate the function of neutrophils (PMNs) and account for increased susceptibility to infection after injury. These effects were investigated by continuously infusing rats with saline or the chemotaxin formyl-methionyl-leucyl-phenylalanine (FMLP). Rats that sustained a full-thickness burn covering 30% of total body surface area and whose wounds were inoculated with Pseudomonas aeruginosa had a significantly shorter survival when FMLP was infused (6.5 +/- 0.91 days) than did saline-infused rats (9.9 +/- 0.83 days). Rats infused with FMLP had significantly more leukocytes in their burn wounds, significantly fewer PMNs in the circulating pool, and the same number of PMNs at the site of FMLP infusion compared with the saline-treated group. These findings support the hypothesis that chemotaxins generated by tissue injury or sepsis contribute to increased susceptibility to infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3800643     DOI: 10.1001/archsurg.1987.01400130117018

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Bacterial translocation and intestinal atrophy after thermal injury and burn wound sepsis.

Authors:  W G Jones; J P Minei; A E Barber; J L Rayburn; T J Fahey; G T Shires; G T Shires
Journal:  Ann Surg       Date:  1990-04       Impact factor: 12.969

2.  The retrospective study on high risk factors of subphrenic infection after hepatectomy.

Authors:  X Xing; Z D Wu
Journal:  J Tongji Med Univ       Date:  1995

3.  The formyl peptide fMLF primes platelet activation and augments thrombus formation.

Authors:  Maryam F Salamah; Divyashree Ravishankar; Rajendran Vaiyapuri; Leonardo A Moraes; Ketan Patel; Mauro Perretti; Jonathan M Gibbins; Sakthivel Vaiyapuri
Journal:  J Thromb Haemost       Date:  2019-05-24       Impact factor: 5.824

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.